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Summary
INTRODUCTION: Croatia launched the National program for the early detection of breast cancer (BC) in 2006. The 
program targets women between the age of 50 and 69 to take a mammogram every two years. About 60% of women per-
formed mammography through the program. The study aimed to determine the difference in breast cancer’s pathohisto-
logic features before and after the introduction of screening.
MATERIALS AND METHODS: Data was collected retrospectively in a single high volume center for women diag-
nosed with invasive BC in the period before the introduction of mammography screening (2005-2007; N=1833), and from 
newly diagnosed (2017-2019; N=2676). Statistical significance of the findings was evaluated using Chi square test.
RESULTS: We recorded a 31.5% increase in the number of patients referred to our hospital in the post-screening period. 
However, no statistically significant reduction in tumor size, histological grade or the number of positive axillary lymph nodes 
was detected in newly diagnosed BC compared to those diagnosed over ten years ago. The mean age of BC incidence was 61 
years, with the mean tumor size of 22 mm (median 18 mm), in both periods. The significant difference occurred in the distribu-
tion of the intrinsic subtypes of BC (P<.001). About 45% of patients were diagnosed with pT1N0 stage, in both periods.
CONCLUSION: In the post-screening period, we treated 32% more newly diagnosed breast cancers. However, patho-
histological features of BC, along with the average tumor size, did not change.
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INTRODUCTION
Breast cancer (BC) is the most prevalent can-
cer in women in Croatia, accounting for 25% of 
cancer incidence in women, according to the Cro-
atian Cancer Registry (1,2). GLOBOCAN (3) re-
port estimated the five-year survival in Croatia for 
BC patients during the 2000-2014 period to 70–
79%, while EUROCARE-5 (4) reported five-year 
survival between 2000-2007 as 76.3% (81.8% in 
eU) (3-8). Despite the progress in diagnostic pro-
cedures and treatment, there is still a 15% higher 
mortality rate of breast cancer in Croatia than in 
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western EU countries (5,6). Kelava et al. (9) re-
ported an increase in the incidence of BC in Croa-
tia 1988-2008 with an estimated annual percentage 
of change of 2.6 %, with a stable mortality rate. A 
presumable explanation was an increase in life-
style-associated risk factors and improvements in 
diagnostics (9). even though women over the age 
of 50 are at higher risk, all age groups are affected. 
The specialized breast units still identify breast le-
sions mainly through ultrasound, mammography, 
and physical examination (10).
Mammography screening programs for BC 
started in the 1980s in some eU countries and they 
registered a mortality reduction of up to 7% with-
in three years of implementation (11). The Gov-
ernment of the Republic of Croatia launched a Na-
tional Program for the Early Detection of Breast 
Cancer in 2006. The program encourages women 
between 50 and 69 years of age to take a mammo-
gram every two years, with a 60% response rate (1, 
5). Since 2006, five cycles of national mammogra-
phy screening were fulfilled, with 3401 new BC 
cases diagnosed (1,2). The latest Croatian cancer 
registry data for 2017 showed a reduction in BC 
mortality (1,2).
The first aim of the program was to reduce 
breast cancer mortality by 15-25% and to detect 
BC in its initial stages, given that 90% of breast 
cancer patients are curable by proper and timely 
diagnosis and treatment with five-year survival 
going up to 96% in such cases (1). Zielonke et al. 
(12) reported a lack of studies from Eastern Euro-
pean countries, including Croatia, on mortality 
status due to screening. apart from the annual re-
ports of the Croatian National Cancer Registry, 
there are only a few articles in Croatia that follow 
the newly diagnosed BCs (9,13-17). Thus, this 
study aimed to look into histopathological fea-
tures of breast cancer in female patients before the 
introduction of the screening and in newly diag-
nosed BC, ten years after.
PATIENTS AND METHODS
We retrospectively analyzed data of BC pa-
tients diagnosed with invasive breast cancer and 
treated consecutively at University Hospital for 
Tumors (Zagreb, Croatia) during two periods: 1) 
from January 1, 2005, to December 31, 2007, and 2) 
from January 1, 2017, and October 31, 2019. We in-
cluded all patients diagnosed with invasive breast 
cancer in selected periods. The first time span was 
chosen because it represents the earliest period for 
that complete data are available in electronic form 
for all pathology reports. in addition, these re-
ports also contain information on Her2 status, 
since an immunohistochemical technique of hor-
mone receptors and Her2 staining was already in 
routine practice, and the Her2 2+ cases were re-
tested using chromogenic in situ hybridization 
method. We extracted the data of all patients with 
invasive breast carcinoma diagnosis without any 
specific criteria, and for some women, not all data 
were available (marked as unknown). The second 
period from 2017 to 2019 was chosen as the most 
recent one, and the data were extracted in the 
same manner.
Data on the age at the time of diagnosis and 
basic histopathological tumor characteristics: his-
tological type, tumor size, histological tumor grade, 
pathological TNM stage, hormone receptor status 
of estrogen (er) and progesterone (pr), human 
epidermal growth factor receptor 2 (Her2), prolif-
eration index (Ki-67) and loco-regional spread of 
the tumor (positive axillary lymph nodes) was col-
lected from pathology reports. Considering that 
Ki-67, which is crucial in distinguishing Luminal 
A (< 20%) from Luminal B, was not analyzed dur-
ing the first study period, for statistical analysis 
we grouped patients with hormone-positive and 
HER2-negative BC (e.g. Luminal type) in one cat-
egory.
apart from descriptive statistics, the groups 
were compared using the Chi-square test with 
Yeats correction by available VassarStats online 
calculator (http://vassarstats.net/newcs.html). The 
cases with unknown status were not included in 
the statistical analysis. Statistically significant P-
values were defined as <0.05.
RESULTS
During three years, from January 1, 2005, to 
December 31, 2007, 1833 women with invasive 
breast cancer (BC) were diagnosed and surgically 
treated at the University Hospital for Tumors. Al-
most all diagnosed patients had surgery as a cura-
tive treatment, after which they underwent adju-
vant chemo/radiotherapy. Table 1 shows that over 
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There was no significant difference in the av-
erage age of patients at the time of diagnosis be-
tween two periods, which was about 61 years (22-
93). During 2005-7, 19.7%  of breast cancer patients 
were younger than 50 years, and 55.7% were be-
tween 50-69 years old, while in the period 2017-19, 
21.4% of patients were younger than 50 years, and 
wise specified (NOS). Between January 1, 2017, 
and October 31, 2019, 2676 patients were diag-
nosed with invasive BC at University Hospital for 
Tumors. During that period, 1748 patients had 
surgery as a curative treatment, after which they 
underwent adjuvant chemo/radiotherapy, 230 pa-
tients had metastatic or recurrent disease, while 
555 patients received neoadjuvant therapy before 
surgery and 143 patients continued their treat-
ment in other institutions after core needle biopsy 
at our hospital. The ductal invasive histological 
type also prevailed (Table 1).
Figure 1. Distribution of the age of breast cancer patients (by age 
groups) at the time of diagnosis during 2005-07 and 2017-19
Table 2.
Comparison of histopathological features of invasive breast cancer and the age of breast cancer patients  












































































* χ2 test, unknown status was not included in analysis
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50.4% were at the age of 50-69 years (Figure 1). In 
both periods, almost 30% of patients were 60-69 
years old, and about 2% of women were younger 
than 35 years. More younger patients received 
neoadjuvant chemotherapy in the 2017-2019 peri-
od (median 55 years), moving the primary surgi-
cal treatment to seemingly older patients (median 
64 years) than in 2005-2007 (median 61).
We did not notice the difference in the medi-
an size of breast cancer (18 mm). More patients 
were diagnosed with tumors smaller than 20 mm 
during 2005-7 (63.2% vs. 60.3%). Nevertheless, in 
both periods, patients younger than 50 years, on 
average, had 2.7 mm larger tumors than patients 
aged 50-69. No statistically significant difference 
was noted in the distribution of histological grade, 
although a small percentage of patients (2.2%) had 
lower histologic grade during the 2017-19 period 
(Table 2).
Figures 2 and 3 depict the minor differences 
in pathologic T and N stages between periods. In 
both periods, most patients were with T1N0 stage 
(45%). No significant difference was found in the 
percentage of patients with a negative axillary 
lymph node status. During both periods, about 
35% of patients had positive lymph nodes (P=.590), 
but we noticed that many more newly diagnosed 
patients did not have axillary dissection (Table 2).
A statistically significant difference in the 
distribution of breast cancer intrinsic subtypes 
was found. Immunohistochemical expression of 
estrogen receptors (ER) was positive in 74.1% of 
patients during the 2005-7 period, and in 85.5% of 
patients during the 2017-19 period. er-positive 
with HER2-negative BC, belonging to the Luminal 
subtype, were found in 65% of patients in the 
 period 2005-7. During 2017-19, we found the lumi-
nal subtype in 67.3% of women, of which 20.9% 
were luminal a. new breast cancer cases in 2017-
19 showed a lower percentage of triple-negative 
(15.0% vs. 10%) (Table 2). Human epidermal 
growth factor receptor 2 (Her2) was positive in 17 
% of BC during the 2005-7 period, while 22.7% of 
BC were HER2-positive during the 2017-2019 pe-
riod. Initially metastatic and recurrent BC in new-
ly diagnosed patients showed a higher percentage 
of positive HER2 (39.3%), while early BC showed 
17.4% of HER2-positive, as in 2005-7.
DISCUSSION
Our analysis recorded a 31.5% increase in the 
number of patients with newly diagnosed breast 
cancer to our Institution. However, no difference 
in the age at diagnosis of BC patients between pe-
riods was recorded. Contrary to our expectations, 
we did not find any significant reduction in tumor 
size, histological grade, or decrease in the percent-
age of women with a loco-regional disease. The 
significant difference was in the distribution of the 
intrinsic subtypes of BC, which might be due to a 
change in the cut-off value in the assessment of 
hormone receptors.
The mean age was 61 years, and about 50% of 
women are in the screening range of 50-69 years, 
while about 20% of women were younger than 50 
years, in both studied periods. This distribution is 
Figure 3. Distribution of pN stage according to the age of breast 
cancer patients (by age groups) at the time of diagnosis during 
2005-2007 and 2017-2019 (N0, tumors without positive lymph 
nodes; N1-3, tumors with one or more positive lymph nodes).
Figure 2. Distribution of pT stage according to the age of breast 
cancer patients (by age groups) at the time of diagnosis during 
2005-07 and 2017-19 (T1, tumor size ≤20 mm; T2, tumor size 
20-50 mm; T3/4, tumor size >50 mm)
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in line with previous reports (18,19). previous 
data from Croatia showed a mean age of breast 
cancer diagnosis at 69 years with a mean size of 
the tumors about 25 mm (17,20). our results were 
similar to those from the Croatian National Can-
cer Registry (2) who reported that 47.9% of wom-
en diagnosed with BC were between the ages of 50 
and 69. They also reported that 18.8% of patients 
were younger than 50 years including 1.7% of 
women diagnosed before age 35, in 2017. Žitnjak 
et al. also found about 2% of women younger than 
35 years at diagnosis (17). Vučić et al. (13) per-
formed research of socio-demographic risk factors 
for BC found that patients who underwent sur-
gery at the University Hospital for Tumors (Za-
greb, Croatia) came from different Croatian Coun-
ties (mainly continental Croatia), but those who 
came from the Mediterranean area, were younger 
at diagnosis. This finding is interesting because 
Croatian Counties show differences in age-stan-
dardized cancer incidence rates in women, rang-
ing from 363.8 (Bjelovarsko-Bilogorska) to 505.1 
(Splitsko-Dalmatinska) (2). Erić et al. (15) found 
that younger patients were more likely to have 
positive lymph nodes than older ones. in split re-
gion, Bezić et al. (20) detected mean size of the tu-
mor about 25 mm and 41.6% with lymph nodes 
positive before the introduction of screening pro-
gram.
Detection of BC in the early clinical stage in-
cludes smaller tumor size, positive hormone re-
ceptors, and negative axillary lymph nodes, re-
sulting in a better prognosis and lower mortality. 
Contrary to our expectations, obtained results 
showed no significant difference in breast cancer 
size between periods, with an average of 21-22 
mm. in newly diagnosed patients, there were 
about 3% fewer patients with tumors below 20 
mm and the same percentage with tumors larger 
than 50 mm. The number of diagnosed patients 
has been growing in recent years, which could be 
the reason for the discrepancy. although the dif-
ference is not statistically significant, we identified 
2.1% of patients with a lower histological grade in 
the period 2017-19. About 35% of women had lo-
co-regional tumor spread in both periods. admit-
tedly, during the period 2017-2019, we observed 
many more patients without axillary dissection, 
so we assume that some of these nodes were nega-
tive at preoperative imaging or that some of these 
patients are still on the neoadjuvant treatment 
protocol, and did not receive surgery at the time of 
analysis. in these patients, we used core needle bi-
opsy, and in such a small tumor sample, it is not 
possible to determine tumor size, histological 
grade, or lymph node status (21). nevertheless, 
the majority of patients had stage T1N0 in both 
periods.
We focused on pathohistological data and 
did not extract data on distant metastases. The 
Croatian Institute of Public Health records a simi-
lar distribution. In 2012, in 46.3% of patients, BC 
was localized, 38.4% of patients had positive axil-
lary lymph nodes, and 7.1% of patients had dis-
tant metastases, while in 2017, in 38.4% of patients, 
BC was diagnosed in the localized stage, 24.7% 
patients had positive axillary lymph nodes, and 
3.7% patients had distant metastases (2,22).
over the last ten years, there were several 
significant changes in the patohistological man-
agement of BC. In 2010, an American Society of 
Clinical Oncology/College of American Patholo-
gists recommended that estrogen receptor (er) 
and progesterone receptors (pgr) are positive if 
there are at least 1% of tumor nuclei are positive 
(23). The previous cut-off was 10%, which is the 
main reason for the higher percentage of hor-
mone-positive tumors in recent period, and also 
affected the distribution of intrinsic subtypes of 
BC (24,25). Another change in clinical practice is 
the determination of Ki-67 crucial for distinguish-
ing Luminal A from Luminal B, which begun rou-
tinely in 2009; thus, we cannot estimate the per-
centage of luminal a tumors in the 2005-7 period 
(24,25). also, our results showed an increase in 
HER2-positive BC in newly diagnosed patients. 
More HER2 analyzes performed on initially meta-
static and recurrent BC, which are more often pos-
itive, may explain the difference. HER2 testing on 
metastatic BC was not a routine in 2005-2007.
Our intention was not to evaluate the effec-
tiveness of mammography screening, but to see 
whether the effects of screening could contribute 
to any improvements in the clinical status of the 
recently diagnosed patients. as a high volume 
breast cancer center (over 800 of BC cases annual-
ly) we have a high referral rate, and our data may 
not detect the screening benefits. Nevertheless, we 
treat one-third of newly diagnosed breast cancers 





Compared to the pre-screening period, we 
currently treat 30% more breast cancer cases. 
However, our results did not show statistically 
significant differences in breast cancer characte-
ristics after the introduction of mammography 
screening. More local/regional single-institution 
data publications could better illustrate both re-
gional specificities and form a good ground for 
optimizing screening and treatment (step forward 
to cancer treatment registries).
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Sažetak
HISTOPATOLOŠKE KARAKTERISTIKE RAKA DOJKE OD 2005 do 2019 U JEDNOM CENTRU U HRVATSKOJ: 
PREGLED PROMJENA NAKON UVOĐENJA MAMMOGRAFSKOG PROBIRA
S. Ramić, M. Perić Balja, V. Ramljak, S. Zadro, I. Kirac, T. Orešić and I. Milas
UVOD: Nacionalni program za mamografski probir raka dojke u Hrvatskoj započeo je 2006, s ciljem otkrivanja raka u 
ranijem stadiju bolesti. Program uključuje mamografski pregled žena u dobi od 50 do 69. Cilj našeg istraživanja je utvrditi 
razlike u patohistološkim karakteristikama raka dojke prije uvođenja probira s novodijagnosticiranim.
MATERIJALI I METODE: Retrospektivno smo u jednom centru prikupili podatke o patohistološkim karakteristikama 
raka dojke bolesnica oboljelih na početku mamografskog probira (2005-2007; N=1833) i podatke o novooboljelima iz raz-
doblja više od deset godina nakon uvedenog probira (2017-2019; N=2676). Dobivene podatke analizirali smo upotrebom 
χ2 testa.
REZULTATI: Zbrinuli smo 31.5% više novodijagnosticiranih bolesnica s karcinomom dojke. Naši rezultati nisu poka-
zali statistički značajne razlike u veličini tumora, histološkom gradusu ili pozitivnom status limfnih čvorova u podpazušnoj 
jami u skupini novodijagnosticiranih bolesnica s karcinomom dojke u usporedbi s onima iz razdoblja prije mamografskog 
probira. Prosječna dob oboljevanja je 61 godina s prosječnom veličinom tumora od 22 mm (medijan 18 mm), u oba razdoblja. 
Oko 45 % bolesnica je dijagnosticirano s pT1N0, u oba razdoblja.
ZAKLJUČAK: U razdoblju nakon uvođenja probira zbrinuli smo 32% više oboljelih od raka dojke u našoj instituciji. 
Nismo zabilježili razlike u patohistološkim karakteristikama tumora, niti u prosječnoj veličini tumora između ova dva 
 perioda.
KLJUČNE RIJEČI: rak dojke, patohistološke karakteristike, mamografski probir
